Rafael Holdings (NYSE: RFL) ramps R&D spend, widens loss on $37.8M cash balance

NodeGuardian

2026-03-28 01:17:34

Abstract generation in progress

Rafael Holdings (NYSE: RFL) reported a wider net loss of $16.2 million for the six months ended January 31, 2026, compared to $13.6 million in the prior year, primarily due to a significant increase in research and development expenses, which rose to $12.0 million from $2.3 million. The company’s revenue increased to $451 thousand, driven by rental income and new product sales. With a cash balance of $37.8 million, Rafael Holdings anticipates having sufficient liquidity for at least the next 12 months as it continues to focus on advancing its lead drug candidate, Trappsol® Cyclo™, through a pivotal Phase 3 clinical trial.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes